Tesamorelin or CJC-1295: what's the difference
Tesamorelin and CJC-1295 are often mentioned side by side, because both are analogues of growth hormone-releasing hormone (GHRH). Beyond that, however, the similarity largely ends: one completed the full path to FDA approval, while the other remained an experimental molecule. The editorial team explains how these peptides differ in structure, pharmacokinetics and the quality of the evidence behind them.
Common origin: GHRH analogues
Natural GHRH is a 44-amino-acid peptide secreted by the hypothalamus that stimulates the somatotroph cells of the pituitary to produce growth hormone (GH). The first 29 amino acids are enough for biological activity, so for decades pharmacologists have modified exactly this fragment, or the full molecule, to obtain more stable analogues.
The problem with native GHRH is its extremely short half-life: the enzyme dipeptidyl peptidase-4 (DPP-4) cleaves off the first two amino acids within minutes, and the molecule loses its activity. Both peptides discussed here were created to get around this limitation, but in different ways.
It is important to understand that neither GHRH analogue is growth hormone. They only enhance the pituitary's own GH secretion, so the effect depends on the integrity of the hypothalamic-pituitary axis and retains a degree of physiological regulation through somatostatin and feedback from insulin-like growth factor 1 (IGF-1).
It is precisely because of this shared mechanism that both substances belong to the same group in the WADA Prohibited List - section S2, «Peptide hormones, growth factors, related substances and mimetics». In other words, from the standpoint of anti-doping rules there is no difference between them.
Molecular structure: the hexenoyl group versus DAC
Tesamorelin is the full 44-amino-acid sequence of human GHRH, with a trans-3-hexenoyl group attached to its N-terminus. This small modification protects the molecule from DPP-4 cleavage, but does not make it long-acting: the drug is administered daily.
CJC-1295 is built on a shortened GHRH(1-29) fragment with four amino-acid substitutions that increase resistance to enzymes. The key feature of the original version is the so-called DAC (drug affinity complex): a reactive group that, after administration, covalently binds to blood albumin.
Binding to albumin turns the peptide into a long-acting one: in the study by Teichman et al. (2006) the half-life of CJC-1295 in healthy adults was approximately 6-8 days. By comparison, tesamorelin has a half-life on the order of tens of minutes.
On the research-peptide market, the version sold under the name «CJC-1295» is often the one without DAC, also called modified GRF(1-29). This is effectively a different substance with short action, and the clinical data on CJC-1295 with DAC cannot be transferred to it.
Pharmacokinetics and the nature of stimulation
The short action of tesamorelin means that after each injection there is a peak of GH secretion that quickly fades. This profile is closer to the natural pulsatile secretion of the hormone, which is considered physiologically favourable.
CJC-1295 with DAC creates prolonged elevated stimulation. In the work by Teichman et al., a single administration raised mean GH concentrations 2-10 fold over six or more days, and IGF-1 levels 1.5-3 fold over 9-11 days. Ionescu and Frohman (2006) showed that pulsatile secretion is preserved in this case, but the basal GH level between peaks rises.
The practical consequence of these differences is differing predictability. A short-acting peptide stops acting within hours after withdrawal, whereas a long-acting analogue continues to stimulate the axis for several more days, and undesirable effects cannot be quickly «switched off».
Both peptides raise IGF-1, which mediates a significant part of the anabolic and metabolic effects of GH. Chronically elevated IGF-1 is associated with fluid retention, worsened insulin sensitivity and theoretical oncological risks, so monitoring this marker is a mandatory part of medical use.
| Parameter | Tesamorelin | CJC-1295 (with DAC) |
|---|---|---|
| Molecular basis | GHRH(1-44) + hexenoyl group | GHRH(1-29) with substitutions + DAC |
| Duration of action | Hours | Days (albumin binding) |
| Regulatory status | FDA-approved (2010) | Not approved in any country |
| Clinical data | Randomized Phase III trials | Early studies in healthy volunteers |
| WADA status | Prohibited (S2) | Prohibited (S2) |
Evidence base: from Phase III to early studies
Tesamorelin has undergone large-scale randomized placebo-controlled trials. In the key study by Falutz et al. (2007), published in the New England Journal of Medicine, the drug reduced visceral fat in patients with HIV-associated lipodystrophy compared with placebo, without substantially worsening glycemic control.
Later studies expanded the picture. Stanley et al. (2014) demonstrated a reduction in liver fat content, and a 2019 multicentre study in the journal Lancet HIV assessed the effect of tesamorelin on non-alcoholic fatty liver disease in people with HIV.
The evidence base for CJC-1295 is considerably more modest. Pharmacokinetic studies in healthy volunteers have been published, confirming its long-lasting action. The developer company discontinued clinical development, and it never reached the stage of efficacy in specific diseases.
So when popular sources present these peptides as equivalent, that is incorrect. For tesamorelin we know the indications, typical side effects and safety profile from the official label, whereas for CJC-1295 we have only the results of short, early studies.
Regulatory status and product quality
Tesamorelin was approved by the FDA in 2010 under the brand name Egrifta to reduce excess abdominal fat in patients with HIV and lipodystrophy. It is a prescription drug with a clear indication, contraindications (including pregnancy and disorders of the hypothalamic-pituitary axis) and monitoring requirements.
CJC-1295 is not registered as a medicine in any country. It is available only as a «research reagent», which means there are no guarantees regarding composition, purity, sterility or even the active substance itself.
Independent analyses of grey-market peptide products have repeatedly found content that does not match the label, impurities and bacterial endotoxins. For an injectable form this constitutes a separate risk, unrelated to the pharmacology of the molecule itself.
For athletes who undergo doping control, there is no difference between the two peptides: both are prohibited at all times, in and out of competition. Modern WADA laboratories are able to detect GHRH analogues using mass spectrometry methods.
- Tesamorelin: a prescription drug with an official label and a known safety profile.
- CJC-1295: an experimental substance without approval or quality control.
- Both: raise IGF-1, require medical supervision, prohibited in sport.
Editorial conclusions
Tesamorelin and CJC-1295 act through the same GHRH receptor, but differ in structure, duration of action and, most importantly, the level of knowledge about them. Tesamorelin is a short-acting approved drug with a Phase III evidence base; CJC-1295 with DAC is a long-acting experimental peptide.
The popular notion that these substances are interchangeable has no scientific basis. Different pharmacokinetics mean a different impact on the GH/IGF-1 axis and different controllability of undesirable effects.
Any use of GHRH analogues is a medical decision that requires examination, monitoring of IGF-1 and glucose, and supervision by an endocrinologist.
The editorial team also recommends reviewing our materials on the mechanism of action of tesamorelin, on the side effects of CJC-1295 and on the status of peptides on the WADA list.
References
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359–2370.
- Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380–389.
- Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821–e830.
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805.
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792–4797.
- U.S. Food and Drug Administration. EGRIFTA (tesamorelin for injection): prescribing information. Silver Spring, MD: FDA.
- World Anti-Doping Agency. The World Anti-Doping Code International Standard: Prohibited List. Montreal: WADA; актуальна редакція.
Andriy Melnyk
A strength-sports coach and author of programs for beginner and intermediate levels. Writes about training planning.
